SavePeptides
SavePeptidesCompound
Re-checked hourly
All peptides
Sexual HealthPhase IIVendors pending
Phase IIVendors pendingFacts verified · 2026-05-25

Kisspeptin-54

Also known as metastin, kiss-1 (68–121) amide, kp-54 · Wikipedia

Kisspeptin-54 (KP-54, metastin) is the full-length 54-amino-acid C-terminally amidated cleavage product of the KISS1 prepropeptide and an agonist at the KISS1R / GPR54 receptor. It is the longer-acting member of the kisspeptin family and the form most rigorously studied in human reproductive endocrinology, particularly as an IVF oocyte-maturation trigger by the Imperial College London group (Dhillo, Abbara, Comninos). It triggers hypothalamic GnRH release, driving LH/FSH secretion and gonadal steroidogenesis, and is being explored as a more physiologic alternative to hCG and GnRH agonist triggers, with apparently lower OHSS risk.

—

best

price

—

per

mg

—

vendors

tracked

Phase II

stage

Vendor data

Coming soon.

Per-vendor pricing and verification tiers populate as the SavePeptides crawler comes online. Until then, browse all approved vendors directly.

Browse all vendors

Mechanism of action

Kisspeptin-54 is the full-length, C-terminally amidated 54-amino-acid product of the KISS1 prepropeptide. Like KP-10 it binds KISS1R (GPR54), a Gq-coupled GPCR on hypothalamic GnRH neurons, but the longer sequence confers higher in-vivo potency and a substantially longer plasma half-life (~28 min SC vs ~4 min for KP-10 IV).

Kisspeptin-54 is the full-length, C-terminally amidated 54-amino-acid product of the KISS1 prepropeptide. Like KP-10 it binds KISS1R (GPR54), a Gq-coupled GPCR on hypothalamic GnRH neurons, but the longer sequence confers higher in-vivo potency and a substantially longer plasma half-life (~28 min SC vs ~4 min for KP-10 IV). KISS1R activation triggers pulsatile GnRH release, driving LH and FSH secretion from the pituitary and downstream gonadal steroidogenesis and oocyte maturation. In IVF, Phase 2 trials by Abbara, Jayasena, and Dhillo (Imperial College London) demonstrated that KP-54 can trigger oocyte maturation in women at high risk of OHSS with reduced incidence of severe OHSS versus hCG (PubMed 26192876).

Pharmacokinetic properties

Half-life

~28 minutes after subcutaneous dosing in humans (vs ~4 min for KP-10 IV)

Routes

subcutaneous · intravenous

Bioavailability

Longer half-life makes SC dosing more practical than KP-10. Oral bioavailability negligible. More expensive to synthesize than KP-10.

Amino-acid sequence

(54 aa) Metastin (1-54), C-terminally amidated

Use & research dosing

Fertility SignalingHPG Axis Support

No FDA-approved dose. In published clinical research, 1.6-12.8 nmol/kg subcutaneous single bolus has been used as an IVF oocyte-maturation trigger, and 0.1-3.0 nmol/kg as an IV bolus in HPG-axis studies. A second-dose 10 h after the first improves oocyte yield in high-OHSS-risk women. Self-experimentation outside fertility-research contexts is uncommon because of cost and limited vendor supply. Research framing only.

Research-use framing only. SavePeptides sells nothing for human consumption. Doses above reflect reported research / self-experimentation ranges, not clinical recommendations.

Editorial perspective

Key distinction from KP-10: same gene product, longer chain, roughly 7x longer plasma half-life, more potent in vivo per molecule. The most rigorous human HPG-axis and IVF data exist for KP-54 rather than KP-10. Imperial College London (Dhillo, Abbara, Comninos, Jayasena) has driven the IVF oocyte-maturation trigger program through Phase 2 trials in high-OHSS-risk women; clinical development beyond Phase 2 has not produced a registered product to date.

— SavePeptides editorial desk · last updated 2026-05-25

Cautions & contraindications

Before researching this compound, note:

  • Not FDA-approved for any indication
  • HPG-axis stimulation inappropriate in hormone-sensitive cancers (breast, prostate, endometrial)
  • Pregnancy and lactation safety unknown outside fertility-trigger trials
  • Risk of OHSS appears reduced versus hCG but is not zero
  • May interfere with hormonal contraception and other HPG-active medications
  • Limited long-term safety data outside Phase 2 trial cohorts
  • IVF use should be in a controlled clinical setting with monitoring
  • Vendor-grade material lacks pharmaceutical sterility and identity assurance

Research foundation

The papers behind the page.

  1. [01]https://pubmed.ncbi.nlm.nih.gov/26192876/
  2. [02]https://pubmed.ncbi.nlm.nih.gov/28854728/

Facts verified

2026-05-25

Confidence

medium

What this means

  • Phase 2 IVF trials only; no Phase 3 / regulatory approval
  • off-label use outside controlled IVF context lacks safety data

How we check →

Vendor data coming soon

All vendors

001 — Independent

We don't list what we wouldn't research.

SavePeptides lists vendors after an initial review and distinguishes verified vendors where additional checks have been completed. We may earn commissions from referral links, and sponsored placements will be clearly disclosed.

002 — Vendor-funded

Free to browse. Supported by referrals.

SavePeptides is free for buyers. We may earn a commission when you order through our links, but we do not lock deals behind a paywall, require an email to view codes, or inflate comparison prices.

003 — Research use

Research-use disclaimer.

SavePeptides surfaces vendor, pricing, and coupon information for research compounds. These products are not intended, approved, or recommended for human consumption. Our content is informational only and does not constitute medical advice.